Dexcom DXCM drew several positive reactions from major banks, with both
Goldman Sachs and
Mizuho initiating coverage with a
Buy rating and
Outperform recommendation respectively. Dexcom's
Q1 revenue beat forecasts, resulting in a 15% increase in stock price and confirming their growth potential. New regulatory approvals, including the longest-lasting wearable CGM system, reinforced DexCom's market dominance. However, it also received an FDA warning letter. Importantly, Dexcom announced a
$750M share buyback and a key personnel promotion, with
Jake Leach appointing as
President and
COO. Key metrics from Q4 earnings missed estimates, yet Dexcom still managed strong revenue growth amid margin challenges. Upcoming product launches and expansion of coverage influenced their positive outlook for 2025. Dexcom was among the diabetes stocks favored by billionaires and saw an increase in price targets from Barclays and Citi. Despite a share price plunge and slow revenue growth, Dexcom is still seen to be a favourable growth stock under $100. Risks include a six-day losing spree, but analysts remain optimistic.
Dexcom DXCM News Analytics from Mon, 23 Sep 2024 07:00:00 GMT to Wed, 04 Jun 2025 17:36:07 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -3
